文献速递儿童青少年精神会诊联络精神医学

注意缺陷多动障碍药物与心血管疾病长期风险

Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

结果显示,较长的累积用药时长与心血管疾病风险升高相关,尤其是高血压和动脉疾病,儿童青少年与成人中模式相似。

要点

  • ADHD药物累积使用3至5年与心血管疾病风险升高相关(AOR 1.27)。
  • 累积使用3至5年及超过5年与高血压风险升高相关(AOR 1.72和1.80)。
  • 随访14年间每增加1年用药,心血管疾病风险增加4%(AOR 1.04)。

核心结论

  • 长期暴露于ADHD药物与心血管疾病风险升高相关,尤其是高血压和动脉疾病。
  • 制定长期ADHD药物治疗决策时需仔细权衡潜在获益与风险。
  • 临床医生应在整个治疗过程中定期持续监测心血管体征和症状。

研究设计与样本

  • 该研究为病例对照研究,纳入2007年1月1日至2020年12月31日期间在瑞典获得ADHD新诊断或ADHD药物处方的6至64岁个体。
  • 暴露为ADHD药物累积使用时长,最长14年;主要结局为 incident CVD。

主要发现

  • 与未使用相比,ADHD药物累积使用1至≤2年AOR 1.09(95% CI 1.01-1.18),2至≤3年AOR 1.15(95% CI 1.05-1.25),3至≤5年AOR 1.27(95% CI 1.17-1.39),>5年AOR 1.23(95% CI 1.12-1.36)。
  • 累积使用3至≤5年与高血压风险升高相关(AOR 1.72,95% CI 1.51-1.97),>5年AOR 1.80(95% CI 1.55-2.08)。
  • 累积使用3至≤5年与动脉疾病风险升高相关(AOR 1.65,95% CI 1.11-2.45),>5年AOR 1.49(95% CI 0.96-2.32)。
  • 14年随访期间,ADHD药物使用每增加1年,心血管疾病风险增加4%(AOR 1.04,95% CI 1.03-1.05),累积使用前3年风险增加更明显(AOR 1.08,95% CI 1.04-1.11),之后风险稳定。
  • 儿童青少年(<25岁)和成人(≥25岁)中观察到相似模式。

关键数值与推荐

  • ADHD药物累积使用0至≤1年与心血管疾病风险无显著关联(AOR 0.99,95% CI 0.93-1.06)。

临床怎么用

  • 长期使用ADHD药物时应定期评估心血管疾病风险,尤其关注高血压和动脉疾病。
  • 治疗决策中需结合患者个体情况权衡ADHD药物的获益与心血管风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Use of attention-deficit/hyperactivity disorder (ADHD) medications has increased substantially over the past decades. However, the potential risk of cardiovascular disease (CVD) associated with long-term ADHD medication use remains unclear. OBJECTIVE: To assess the association between long-term use of ADHD medication and the risk of CVD. DESIGN, SETTING, AND PARTICIPANTS: This case-control study included individuals in Sweden aged 6 to 64 years who received an incident diagnosis of ADHD or ADHD medication dispensation between January 1, 2007, and December 31, 2020. Data on ADHD and CVD diagnoses and ADHD medication dispensation were obtained from the Swedish National Inpatient Register and the Swedish Prescribed Drug Register, respectively. Cases included individuals with ADHD and an incident CVD diagnosis (ischemic heart diseases, cerebrovascular diseases, hypertension, heart failure, arrhythmias, thromboembolic disease, arterial disease, and other forms of heart disease). Incidence density sampling was used to match cases with up to 5 controls without CVD based on age, sex, and calendar time. Cases and controls had the same duration of follow-up. EXPOSURE: Cumulative duration of ADHD medication use up to 14 years. MAIN OUTCOMES AND MEASURES: The primary outcome was incident CVD. The association between CVD and cumulative duration of ADHD medication use was measured using adjusted odds ratios (AORs) with 95% CIs. RESULTS: Of 278 027 individuals with ADHD aged 6 to 64 years, 10 388 with CVD were identified (median [IQR] age, 34.6 [20.0-45.7] years; 6154 males [59.2%]) and matched with 51 672 control participants without CVD (median [IQR] age, 34.6 [19.8-45.6] years; 30 601 males [59.2%]). Median (IQR) follow-up time in both groups was 4.1 (1.9-6.8) years. Longer cumulative duration of ADHD medication use was associated with an increased risk of CVD compared with nonuse (0 to ≤1 year: AOR, 0.99 [95% CI, 0.93-1.06]; 1 to ≤2 years: AOR, 1.09 [95% CI, 1.01-1.18]; 2 to ≤3 years: AOR, 1.15 [95% CI, 1.05-1.25]; 3 to ≤5 years: AOR, 1.27 [95% CI, 1.17-1.39]; and >5 years: AOR, 1.23 [95% CI, 1.12-1.36]). Longer cumulative ADHD medication use was associated with an increased risk of hypertension (eg, 3 to ≤5 years: AOR, 1.72 [95% CI, 1.51-1.97] and >5 years: AOR, 1.80 [95% CI, 1.55-2.08]) and arterial disease (eg, 3 to ≤5 years: AOR, 1.65 [95% CI, 1.11-2.45] and >5 years: AOR, 1.49 [95% CI, 0.96-2.32]). Across the 14-year follow-up, each 1-year increase of ADHD medication use was associated with a 4% increased risk of CVD (AOR, 1.04 [95% CI, 1.03-1.05]), with a larger increase in risk in the first 3 years of cumulative use (AOR, 1.08 [95% CI, 1.04-1.11]) and stable risk over the remaining follow-up. Similar patterns were observed in children and youth (aged <25 years) and adults (aged ≥25 years). CONCLUSIONS AND RELEVANCE: This case-control study found that long-term exposure to ADHD medications was associated with an increased risk of CVDs, especially hypertension and arterial disease. These findings highlight the importance of carefully weighing potential benefits and risks when making treatment decisions about long-term ADHD medication use. Clinicians should regularly and consistently monitor cardiovascular signs and symptoms throughout the course of treatment.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Zhang L, Li L, Andell P, et al. Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases. JAMA Psychiatry. 2024. PMID: 37991787. doi:10.1001/jamapsychiatry.2023.4294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。